Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis
Shots:
- InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones- following the achievement of definite milestones along with royalties on sales of any product resulting from the collaboration
- Biogen to get exclusive rights for orelabrutinib to treat MS globally & other autoimmune diseases outside of China while InnoCare will retain exclusive WW rights to the therapy in the field of oncology & other autoimmune diseases in China
- Orelabrutinib is a covalent BTKi with high selectivity & has the potential to cross the BBB. Additionally- the therapy is currently being evaluated in a P-II trial for RRMS
Ref: Globe Newswire | Image: Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
